Correlation Between Thioredoxin-Interacting Protein and Nerve Conduction Velocity in Patients With Type 2 Diabetes Mellitus

Aims: To investigate the correlation between thioredoxin-interacting protein (TXNIP) and peripheral nerve conduction velocity (NCV) in patients with type 2 diabetes mellitus. Methods: In total, 338 patients with type 2 diabetes mellitus (T2DM) were included in this study. We collected the clinical data and measured the motor conduction velocities of the bilateral ulnar nerve, median nerve, tibial nerve, and common peroneal nerve, and the sensory conduction velocities of the ulnar nerve, median nerve, sural nerve, and superficial peroneal nerve. According to the results, the patients were divided into two groups: normal peripheral nerve conduction group (NCVN group) and abnormal peripheral nerve conduction group (NCVA group). The two groups were then compared in terms of the conventional biochemical index and the sugar metabolic index as well as the serum levels of TXNIP, reduced glutathione (GSH), total superoxide dismutase (SOD), malondialdehyde (MDA), and tumor necrosis factor alpha (TNF-α). The correlation between TXNIP and NCV was also analyzed. Results: Compared with the NCVN group, the TXNIP and MDA values were significantly increased in the NCVA group (P < 0.05). Among the patients with T2DM, age, fasting glucose, SDBG, and TXNIP were risk factors for NCV abnormality, while vitamin D3 was a protective factor. After adjusting for related confounding factors, TXNIP was significantly correlated with NCV (P < 0.05). Among the patients with T2DM, TXNIP was an independent risk factor for left ulnar motor conduction velocity (MCV), right ulnar MCV, left median MCV, and right median MCV. TNF-α was identified as a positive influencing factor for serum TXNIP, while serum TXNIP was a positive factor for TNF-α and MDA (both P < 0.05). Conclusion: Serum TXNIP is related to NCV in T2DM patients. In combination with oxidative stress and inflammation, TXNIP may affect diabetic peripheral neuropathy (DPN).

[1]  Yue Shi,et al.  Jinmaitong Ameliorates Diabetic Peripheral Neuropathy Through Suppressing TXNIP/NLRP3 Inflammasome Activation In The Streptozotocin-Induced Diabetic Rat Model , 2019, Diabetes, metabolic syndrome and obesity : targets and therapy.

[2]  G. Qin,et al.  The mechanisms of glycemic variability accelerate diabetic central neuropathy and diabetic peripheral neuropathy in diabetic rats. , 2019, Biochemical and biophysical research communications.

[3]  Meiping Guan,et al.  Verapamil Attenuated Prediabetic Neuropathy in High-Fat Diet-Fed Mice through Inhibiting TXNIP-Mediated Apoptosis and Inflammation , 2019, Oxidative medicine and cellular longevity.

[4]  H. El-Mesallamy,et al.  Serum Vitamin D and Its Upregulated Protein, Thioredoxin Interacting Protein, Are Associated With Beta-Cell Dysfunction in Adult Patients With Type 1 and Type 2 Diabetes. , 2018, Canadian journal of diabetes.

[5]  Yibo Yu,et al.  The Function of Thioredoxin-Binding Protein-2 (TBP-2) in Different Diseases , 2018, Oxidative medicine and cellular longevity.

[6]  I. Lee,et al.  Variability of fasting plasma glucose and the risk of painful diabetic peripheral neuropathy in patients with type 2 diabetes. , 2018, Diabetes & metabolism.

[7]  S. Nasoohi,et al.  Thioredoxin-Interacting Protein (TXNIP) in Cerebrovascular and Neurodegenerative Diseases: Regulation and Implication , 2018, Molecular Neurobiology.

[8]  M. Aziz,et al.  TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook , 2017, Current drug targets.

[9]  M. Yaman,et al.  Does vitamin D have any role in the improvement of diabetic peripheral neuropathy in type 1 diabetic patients? , 2016, Journal of Endocrinological Investigation.

[10]  T. Park,et al.  Recent Advances in Diagnostic Strategies for Diabetic Peripheral Neuropathy , 2016, Endocrinology and metabolism.

[11]  P. Kruzliak,et al.  Single nucleotide polymorphisms in the Trx2/TXNIP and TrxR2 genes of the mitochondrial thioredoxin antioxidant system and the risk of diabetic retinopathy in patients with Type 2 diabetes mellitus. , 2016, Journal of diabetes and its complications.

[12]  P. Villoslada,et al.  The disruption of mitochondrial axonal transport is an early event in neuroinflammation , 2015, Journal of Neuroinflammation.

[13]  Xinsheng Li,et al.  Retrospective analysis of the relationship between elevated plasma levels of TXNIP and carotid intima-media thickness in subjects with impaired glucose tolerance and early Type 2 diabetes mellitus. , 2015, Diabetes research and clinical practice.

[14]  A. Höke,et al.  Mechanisms of distal axonal degeneration in peripheral neuropathies , 2015, Neuroscience Letters.

[15]  Yujie Jia,et al.  Significance of functional GRP78 polymorphisms in predicting the onset of type 2 diabetic peripheral neuropathy in Chinese population , 2015, Neurological research.

[16]  I. G. Fantus,et al.  Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[17]  M. Guzmán,et al.  Glycemic Control and Oxidative Stress Markers and their relationship with the Thioredoxin Interacting Protein (TXNIP) gene in Type 2 Diabetic patients , 2014 .

[18]  J. Horowitz,et al.  Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes , 2014, Cardiovascular Drugs and Therapy.

[19]  Navpreet Kaur,et al.  Diabetic peripheral neuropathy: current perspective and future directions. , 2014, Pharmacological research.

[20]  Finn Sellebjerg,et al.  CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis , 2013, Multiple sclerosis.

[21]  Pablo Villoslada,et al.  Oxidative Stress and Proinflammatory Cytokines Contribute to Demyelination and Axonal Damage in a Cerebellar Culture Model of Neuroinflammation , 2013, PloS one.

[22]  B. Berk,et al.  Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. , 2012, Antioxidants & redox signaling.

[23]  I. G. Fantus,et al.  Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells. , 2010, Cellular signalling.

[24]  E. Feldman,et al.  Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy , 2010, Acta Neuropathologica.

[25]  A. Shalev,et al.  Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. , 2009, American journal of physiology. Endocrinology and metabolism.

[26]  L. Zeef,et al.  Thioredoxin interacting protein is increased in sensory neurons in experimental diabetes , 2006, Brain Research.

[27]  A. Hayes,et al.  Identification of Changes in Gene Expression in Dorsal Root Ganglia in Diabetic Neuropathy: Correlation With Functional Deficits , 2006, Journal of neuropathology and experimental neurology.

[28]  P. Dyck,et al.  Diabetic Neuropathies: Classification, Clinical Features, and Pathophysiological Basis , 2005, The neurologist.

[29]  V. Mohan,et al.  Prevalence of neuropathy in type 2 diabetic patients attending a diabetes centre in South India. , 2002, The Journal of the Association of Physicians of India.